抗HBV-DC联合药物治疗e抗原阳性的临床研究  

Preliminary clinical study of anti-HBV-DC combine lamivudine and thymosin α1 treat the HBeAg positive chronic hepatitis B patients

作　　者：刘勇 吴邦富[1] 胡媛媛[1] 

机构地区：[1]南方医科大学仁康医院消化肝病中心,广东东莞523952

出　　处：《中国现代医生》2012年第1期77-79,共3页China Modern Doctor

摘　　要：目的观察HBsAg致敏自体外周血单个核细胞(PBMC)来源的树突状细胞联合拉米夫定和胸腺肽α1治疗HBeAg阳性慢乙肝的临床效果。方法 HBeAg阳性CHB患者20例接受临床研究。取肝素抗凝外周静脉血50mL,以密度梯度离心及贴壁法获得PBMC,GM-CSF和IL-4诱导扩增DC,第6天给予30μg的HBsAg致敏DC,第7天收获抗HBV-DC。联合拉米夫定和胸腺肽α1,分别于0、4、12周检测HBVM定量和HBV-DNA定量及肝功能。结果全部患者治疗后4、12周的HBsAg、HBeAg和HBV-DNA均明显下降。总有效率100%(20/20)。结论抗HBV-DC联合拉米夫定和胸腺肽α1治疗,可快速降低血中HBsAg、HBeAg和HBV-DNA,促进HBeAb的产生,提高HBeAg/HBeAb的血清学转换率。Objective To observe the clinical treatment effects of the HBsAg pulsed autologous dendritic cells derived from peripheral blood mononuclear cells （PBMC） combine lamivudine and Thymosin-α1 for the HBeAg positive chronic hepatitis B patients. Methods Twenty patients with HBeAg positive CHB accepted by clinical research. Taking peripheral venous blood 50mL, by density gradient eentrifugation and adhesion method to obtain PBMC, GM-CSF and IL-4 induced expansion of DC. At the sixth days, a 30 μg HBsAg was give to pulse the DC. At the seventh days, the anti-HBV-DCs. All patients were Lamivudine dosed every day, and were injected thymosin-α1 by subcutaneous, The HBVM, HBV-DNA and liver function were respectively detected at 0,4,12 weeks. Results At 0,4,12 weeks, the serum HBsAg levels, the serum HBeAg levels and the serum HBV-DNA levels were significantly decreased. The total effective rate was 100% （20/20）. Conclusion The anti-HBV-DC by subcutaneous and intravenous injection combine lamivudine and Thymosin-α1 can decrease rapid the serum HBsAg, HBeAg and HBV-DNA levels, promote to the HBeAb production, and enhance the HBeAg/HBeAb seroconversion late.

关 键 词：树突状细胞 慢性乙型肝炎 乙肝疫苗 

分 类 号：R512.62[医药卫生—内科学]